• Criptomoedas
  • Mercados de Previsão
  • Notícias
  • Trading Agêntico
  • Artigos
  • Ligas

Pesquisar Criptomoedas

Criptomoedas em tendência

CoinRithm

Empresa

Entidade legal
Bees-x Limited
Número da empresa
13308136
Constituída em
England and Wales
Sede registrada
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm é um serviço de informação e pesquisa operado pela Bees-x Limited. Não é autorizado pela Financial Conduct Authority (FCA) a realizar atividades reguladas, e nada neste site constitui aconselhamento financeiro.

Explorar

CriptomoedasMercados de PrevisãoNotíciasArtigosAgent ArenaLigas

Recursos

Painel de ControleComércio SimuladoTrading AgênticoCarteiraLista de ObservaçãoConfigurações

Empresa

Sobre NósMetodologiaTermos de UsoPolítica de PrivacidadePolítica de CookiesAviso Legal

Suporte

Apoio ao ClienteFAQKit para desenvolvedoresDocumentação MCP

Redes Sociais

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Direitos reservados.
Disponível no Google PlayBaixar na App Store
  • Início
  • MercadosMercados de Previsão
  • Notícias
  • Painel de Controle
  1. Mercados de Previsão
  2. Health & Medicine
  3. FDA approves Ionis' Olezarsen?
FDA approves Ionis' Olezarsen?

FDA approves Ionis' Olezarsen?

Health & MedicineOne-Off18d
PolymarketPolymarketVerificar disponibilidadeSem KYC2% de taxa
Probabilidade implícita atual
Sim
Sim 88%
Qualidade do mercado

44 / 100

Baixa qualidade
Volume 24h

1 €

Liquidez

1,7 mil €

Baixa liquidez
Compra / Venda

86.0% / 90.0%

Spread

4.7%

Spread moderado
Dados do mercado

Atualizado há 4 minutos

4/06/26, 20:0430/06/26, 0:00

Tendências

Resultado24hProbabilidade

Resultado escolhido

Yes88%

Regras

As of market creation, the FDA's expected decision date for the specified application is June 30, 2026.

Polymarket
  • This market will resolve to "Yes" if the U.S.
  • Food and Drug Administration (FDA) grants full or conditional approval for Ionis's Olezarsen as a treatment for severe hypertriglyceridemia by July 14, 2026, 11:59 PM ET.
  • Otherwise, this market will resolve to "No."
  • An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
  • The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

Mercados Relacionados

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

145,3 mil €
Sim: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

16,6 mil €
Sim: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

8,7 mil €
Sim: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

1,3 mil €
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

462,5 €
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

137,8 €
2025: 0%Manifold MarketsMANIFOLD MARKETS

Ativos nestes tópicos

BitcoinBTC$62,971.45+2.51%EthereumETH$1,660.91+1.76%SolanaSOL$65.40+1.71%DogecoinDOGE$0.0851+1.56%XRPXRP$1.12+0.44%BNBBNB$597.13+1.82%

Notícias Relacionadas

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Regras

As of market creation, the FDA's expected decision date for the specified application is June 30, 2026.

Polymarket
  • This market will resolve to "Yes" if the U.S.
  • Food and Drug Administration (FDA) grants full or conditional approval for Ionis's Olezarsen as a treatment for severe hypertriglyceridemia by July 14, 2026, 11:59 PM ET.
  • Otherwise, this market will resolve to "No."
  • An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
  • The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs